Welcome to our dedicated page for Abbott Labs news (Ticker: ABT), a resource for investors and traders seeking the latest updates and insights on Abbott Labs stock.
Abbott Laboratories (NYSE: ABT) generates a steady flow of news across diagnostics, medical devices, nutritionals and branded generic medicines, reflecting its role as a global healthcare company serving people in more than 160 countries. News coverage on this page highlights regulatory milestones, product launches, clinical data, corporate actions and community initiatives that shape Abbott’s business and its impact on patients.
Recent announcements include FDA approvals and clearances for cardiovascular and structural heart technologies, such as the Volt PFA System for treating atrial fibrillation and the Amplatzer Piccolo Delivery System for minimally invasive closure of patent ductus arteriosus in premature infants. Abbott also reports developments in diabetes care and metabolic health, including enhancements to its Libre app through the Libre Assist feature, which uses generative AI and continuous glucose monitoring data to help people living with diabetes understand how food choices may affect glucose levels, and the expansion of its Lingo over-the-counter continuous glucose monitor to additional mobile platforms.
Investors and observers will also find news about Abbott’s nutrition business, such as new Ensure Max Protein shakes aimed at supporting muscle health for active and older adults, as well as information on public health partnerships and community programs like the "We Give Blood" competition with the Big Ten Conference and the HeartMates community for people with heart health challenges. Corporate updates include dividend declarations and increases, as well as the announced Agreement and Plan of Merger to acquire Exact Sciences Corporation, which would expand Abbott’s presence in cancer screening and precision oncology diagnostics.
This news feed provides a centralized view of Abbott’s latest announcements, allowing readers to follow developments in its key business segments and understand how new products, regulatory events and strategic transactions may influence the company over time.
Abbott is actively engaged in pandemic prevention through its Pandemic Defense Coalition, focusing on virus surveillance globally, from the Amazon to urban centers in India. A new collaboration with Warner Bros. Discovery has produced a branded series titled The Virus Hunt, showcasing efforts to identify COVID-19 variants, starting in South Africa. Abbott's 2030 Sustainability Plan aims to improve the health of 3 billion people annually by enhancing access to its innovative healthcare products and technologies. The company is committed to sustainable management practices to make a long-term impact on global health.
Abbott has announced significant partnerships aimed at enhancing diabetes management through advanced technology. The collaborations, which include companies like Bigfoot Biomedical, Insulet, Novo Nordisk, Sanofi, Tandem, and Ypsomed, focus on integrating Abbott's FreeStyle Libre systems with various insulin delivery methods. This synergy is expected to simplify diabetes care for approximately 63 million insulin-dependent individuals globally. The initiatives are part of Abbott's strategy to create seamless, personalized care, enabling users to make informed treatment decisions and improve their overall management of diabetes.
Abbott (NYSE: ABT) announced FDA approval for its Proclaim™ XR spinal cord stimulation (SCS) system, targeting painful diabetic peripheral neuropathy (DPN). This innovative system offers a non-medication alternative for the estimated 34.2 million Americans living with diabetes, of whom about 50% may develop neuropathy. The Proclaim XR SCS system is designed for hassle-free pain relief with a battery life of up to 10 years. This approval enhances Abbott's commitment to providing comprehensive diabetes care solutions, allowing patients to seamlessly manage pain while improving their quality of life.
Abbott (NYSE: ABT) reported fourth-quarter 2022 sales of $10.1 billion, down 12% year-over-year, mainly due to a decline in COVID-19 testing-related sales. Full-year sales reached $43.7 billion, growing 1.3% overall and 6.4% organically. GAAP diluted EPS for the fourth quarter was $0.59 and adjusted EPS was $1.03. For 2023, Abbott projects GAAP EPS of $3.05 to $3.25 and adjusted EPS of $4.30 to $4.50. The company continues to focus on innovation, highlighted by recent FDA approvals of new medical devices.
Abbott (NYSE:ABT) has partnered with Blood Centers of America to launch a pioneering mixed reality experience aimed at enhancing the blood donation process. This technology, showcased at CES 2023, is controlled entirely through eye tracking and provides donors with an immersive digital environment. The initiative seeks to attract younger blood donors amid a declining donor rate, particularly among those under 30. Currently being piloted at select locations, the mixed reality experience is designed to make the donation process more engaging and appealing to potential donors.
Abbott (NYSE: ABT) announced FDA approval for its Navitor system, designed for transcatheter aortic valve implantation (TAVI) to treat severe aortic stenosis in patients at high or extreme surgical risk. The Navitor device reduces risk of blood leakage around the valve, enhancing patient care. It includes a unique NaviSeal fabric cuff to minimize paravalvular leak and is the only self-expanding TAVI system with leaflets within the native valve, improving future coronary artery access. This system supports optimal blood flow, further solidifying Abbott's strategy in minimally invasive heart disease treatments.
Ra Medical Systems has completed a stock-for-stock merger with Catheter Precision, aimed at enhancing its cardiac electrophysiology market presence. David Jenkins, CEO of Catheter Precision, will serve as Executive Chairman. The transaction includes a conversion of $25 million in debt to non-voting Convertible Preferred Stock, granting Catheter Precision stakeholders approximately 87.7% of RMED’s equity. Ra Medical anticipates raising up to $9.3 million in equity financing, reinforcing its financial position with an estimated $12.5 million in net cash for two years of operating capital.
Abbott has partnered with Blood Centers of America to launch a pioneering mixed reality experience aimed at enhancing the blood donation process. This innovative technology, showcased at CES 2023, uses eye tracking to create an engaging digital environment for donors, addressing the decline in donations among younger individuals. Currently in pilot at select locations, this initiative seeks to improve the overall donation experience while ensuring donor safety. The initiative targets increasing the donation rate among the under-30 demographic, which has seen a significant decline.
Abbott (NYSE: ABT) is set to release its fourth-quarter 2022 financial results on January 25, 2023, prior to market opening. Following the announcement, a live webcast of the earnings conference call will take place at 8 a.m. CT (9 a.m. ET), accessible via Abbott's Investor Relations website. Abbott is a leading global healthcare firm with a diverse portfolio, including diagnostics, medical devices, nutritionals, and branded generic medicines, serving over 160 countries with a workforce of approximately 113,000 employees.
Abbott has announced that its FreeStyle Libre 3 sensor is now integrated with the mylife™ Loop automated insulin delivery (AID) system, marking a significant advancement in diabetes management. This innovative system, available in Germany and expanding to other European countries in 2023, automates insulin delivery based on real-time glucose data, simplifying diabetes care. Currently, this solution is not available in the United States. With over 4.5 million users, Abbott aims to enhance glucose control, helping many regain lost healthy years due to inadequate diabetes management.